




PHARMACEUTICAL 2018

Zyla Life Sciences
Rank 286 of 342





PHARMACEUTICAL 2018

Zyla Life Sciences
Rank 286 of 342

The relative strengths and weaknesses of Zyla Life Sciences are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zyla Life Sciences compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Zyla Life Sciences is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is -98%, being 143% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	101,953
Cost of Goods Sold	0
Intangible Assets	6,583
Liabilities, Current	42,967
Liabilities, Non-Current	99,617
Other Assets	1,411
Other Compr. Net Income	908
Other Expenses	45,527
Other Liabilities	16,649
Other Net Income	-1,159
Other Revenues	26,136
Property and Equipment	9,911
Research and Development	14,744
Selling, General and Administrative Expense	34,065

Output Variable	Value in 1000 USD
Assets	119,858
Liabilities	159,233
Expenses	94,336
Revenues	26,136
Stockholders Equity	-39,375
Net Income	-69,359
Comprehensive Net Income	-68,905
Economic Capital Ratio	-98%